FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916422396> ?p ?o ?g. }

• W2916422396 endingPage "24" @default.
• W2916422396 startingPage "14" @default.
• W2916422396 abstract "•HCV clearance is associated with a high number of cross-genotype specific antibodies. •Antigenic region 3 (AR3) is the dominant epitope recognized by the antibodies. •AR3-specific antibodies neutralized HCV pseudoparticles and cell culture viruses. •A large number of clearers develop antibodies targeting antigenic region 4 (AR4). •AR4-specific antibody AT1618 also neutralized neutralization-resistant variants. Background & Aims In order to design an effective vaccine against hepatitis C virus (HCV) infection, it is necessary to understand immune protection. A number of broadly reactive neutralizing antibodies have been isolated from B cells of HCV-infected patients. However, it remains unclear whether B cells producing such antibodies contribute to HCV clearance and long-term immune protection against HCV. Methods We analysed the B cell repertoire of 13 injecting drug users from the Amsterdam Cohort Study, who were followed up for a median of 17.5 years after primary infection. Individuals were classified into 2 groups based on the outcome of HCV infection: 5 who became chronically infected either after primary infection or after reinfection, and 8 who were HCV RNA negative following spontaneous clearance of ≥1 HCV infection(s). From each individual, 10,000 CD27+IgG+B cells, collected 0.75 year after HCV infection, were cultured to characterize the antibody repertoire. Results Using a multiplex flow cytometry-based assay to study the antibody binding to E1E2 from genotype 1 to 6, we found that a high frequency of cross-genotype antibodies was associated with spontaneous clearance of 1 or multiple infections (p = 0.03). Epitope specificity of these cross-genotype antibodies was determined by alanine mutant scanning in 4 individuals who were HCV RNA negative following spontaneous clearance of 1 or multiple infections. Interestingly, the cross-genotype antibodies were mainly antigenic region 3 (AR3)-specific and showed cross-neutralizing activity against HCV. In addition to AR3 antibodies, 3 individuals developed antibodies recognizing antigenic region 4, of which 1 monoclonal antibody showed cross-neutralizing capacity. Conclusions Together, these data suggest that a strong B cell response producing cross-genotype and neutralizing antibodies, especially targeting AR3, contributes to HCV clearance and long-term immune protection against HCV. Lay summary Although effective treatments against hepatitis C virus (HCV) are available, 500,000 people die from liver disease caused by HCV each year and approximately 1.75 million people are newly infected. This could be prevented by a vaccine. To design a vaccine against HCV, more insight into the role of antibodies in the protection against HCV infection is needed. In a cohort of injecting drug users, we found that antibodies interfering with virus cell entry, and recognizing multiple HCV genotypes, conferred long-term protection against chronic HCV infection. In order to design an effective vaccine against hepatitis C virus (HCV) infection, it is necessary to understand immune protection. A number of broadly reactive neutralizing antibodies have been isolated from B cells of HCV-infected patients. However, it remains unclear whether B cells producing such antibodies contribute to HCV clearance and long-term immune protection against HCV. We analysed the B cell repertoire of 13 injecting drug users from the Amsterdam Cohort Study, who were followed up for a median of 17.5 years after primary infection. Individuals were classified into 2 groups based on the outcome of HCV infection: 5 who became chronically infected either after primary infection or after reinfection, and 8 who were HCV RNA negative following spontaneous clearance of ≥1 HCV infection(s). From each individual, 10,000 CD27+IgG+B cells, collected 0.75 year after HCV infection, were cultured to characterize the antibody repertoire. Using a multiplex flow cytometry-based assay to study the antibody binding to E1E2 from genotype 1 to 6, we found that a high frequency of cross-genotype antibodies was associated with spontaneous clearance of 1 or multiple infections (p = 0.03). Epitope specificity of these cross-genotype antibodies was determined by alanine mutant scanning in 4 individuals who were HCV RNA negative following spontaneous clearance of 1 or multiple infections. Interestingly, the cross-genotype antibodies were mainly antigenic region 3 (AR3)-specific and showed cross-neutralizing activity against HCV. In addition to AR3 antibodies, 3 individuals developed antibodies recognizing antigenic region 4, of which 1 monoclonal antibody showed cross-neutralizing capacity. Together, these data suggest that a strong B cell response producing cross-genotype and neutralizing antibodies, especially targeting AR3, contributes to HCV clearance and long-term immune protection against HCV." @default.
• W2916422396 created "2019-03-02" @default.
• W2916422396 creator A5004466558 @default.
• W2916422396 creator A5021185852 @default.
• W2916422396 creator A5023123142 @default.
• W2916422396 creator A5027506027 @default.
• W2916422396 creator A5027895154 @default.
• W2916422396 creator A5028386801 @default.
• W2916422396 creator A5039767648 @default.
• W2916422396 creator A5045448757 @default.
• W2916422396 creator A5062827814 @default.
• W2916422396 creator A5066523822 @default.
• W2916422396 creator A5072207419 @default.
• W2916422396 creator A5075604032 @default.
• W2916422396 creator A5077325656 @default.
• W2916422396 creator A5089955013 @default.
• W2916422396 date "2019-07-01" @default.
• W2916422396 modified "2023-09-24" @default.
• W2916422396 title "Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance" @default.
• W2916422396 cites W1521591765 @default.
• W2916422396 cites W1569603086 @default.
• W2916422396 cites W1967491261 @default.
• W2916422396 cites W1970691866 @default.
• W2916422396 cites W2006118213 @default.
• W2916422396 cites W2007149475 @default.
• W2916422396 cites W2015878390 @default.
• W2916422396 cites W2037494007 @default.
• W2916422396 cites W2047619471 @default.
• W2916422396 cites W2069910822 @default.
• W2916422396 cites W2087252539 @default.
• W2916422396 cites W2090297731 @default.
• W2916422396 cites W2100260641 @default.
• W2916422396 cites W2100446424 @default.
• W2916422396 cites W2102253058 @default.
• W2916422396 cites W2108362208 @default.
• W2916422396 cites W2111996375 @default.
• W2916422396 cites W2118407630 @default.
• W2916422396 cites W2120220648 @default.
• W2916422396 cites W2122043154 @default.
• W2916422396 cites W2140516603 @default.
• W2916422396 cites W2143237309 @default.
• W2916422396 cites W2148495628 @default.
• W2916422396 cites W2151557253 @default.
• W2916422396 cites W2165383743 @default.
• W2916422396 cites W2166549128 @default.
• W2916422396 cites W2169973283 @default.
• W2916422396 cites W2196594662 @default.
• W2916422396 cites W2218122840 @default.
• W2916422396 cites W2532535903 @default.
• W2916422396 cites W2544261095 @default.
• W2916422396 cites W2545259858 @default.
• W2916422396 cites W2605698336 @default.
• W2916422396 cites W2611776159 @default.
• W2916422396 cites W2780150340 @default.
• W2916422396 cites W2915321609 @default.
• W2916422396 doi "https://doi.org/10.1016/j.jhep.2019.02.013" @default.
• W2916422396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30797052" @default.
• W2916422396 hasPublicationYear "2019" @default.
• W2916422396 type Work @default.
• W2916422396 sameAs 2916422396 @default.
• W2916422396 citedByCount "25" @default.
• W2916422396 countsByYear W29164223962019 @default.
• W2916422396 countsByYear W29164223962020 @default.
• W2916422396 countsByYear W29164223962021 @default.
• W2916422396 countsByYear W29164223962022 @default.
• W2916422396 countsByYear W29164223962023 @default.
• W2916422396 crossrefType "journal-article" @default.
• W2916422396 hasAuthorship W2916422396A5004466558 @default.
• W2916422396 hasAuthorship W2916422396A5021185852 @default.
• W2916422396 hasAuthorship W2916422396A5023123142 @default.
• W2916422396 hasAuthorship W2916422396A5027506027 @default.
• W2916422396 hasAuthorship W2916422396A5027895154 @default.
• W2916422396 hasAuthorship W2916422396A5028386801 @default.
• W2916422396 hasAuthorship W2916422396A5039767648 @default.
• W2916422396 hasAuthorship W2916422396A5045448757 @default.
• W2916422396 hasAuthorship W2916422396A5062827814 @default.
• W2916422396 hasAuthorship W2916422396A5066523822 @default.
• W2916422396 hasAuthorship W2916422396A5072207419 @default.
• W2916422396 hasAuthorship W2916422396A5075604032 @default.
• W2916422396 hasAuthorship W2916422396A5077325656 @default.
• W2916422396 hasAuthorship W2916422396A5089955013 @default.
• W2916422396 hasBestOaLocation W29164223962 @default.
• W2916422396 hasConcept C104317684 @default.
• W2916422396 hasConcept C135763542 @default.
• W2916422396 hasConcept C14086860 @default.
• W2916422396 hasConcept C147483822 @default.
• W2916422396 hasConcept C159047783 @default.
• W2916422396 hasConcept C159654299 @default.
• W2916422396 hasConcept C195616568 @default.
• W2916422396 hasConcept C203014093 @default.
• W2916422396 hasConcept C2522874641 @default.
• W2916422396 hasConcept C2776408679 @default.
• W2916422396 hasConcept C55493867 @default.
• W2916422396 hasConcept C71924100 @default.
• W2916422396 hasConcept C86803240 @default.
• W2916422396 hasConcept C8891405 @default.
• W2916422396 hasConceptScore W2916422396C104317684 @default.
• W2916422396 hasConceptScore W2916422396C135763542 @default.

• next